Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers.

Abstract

Objectives:

The use of liquid biopsies (LB) in patients with solid malignancies enables comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) and has the potential to guide therapy stratification and support disease monitoring. To examine clinical uptake of LB in a real-world setting, LB implementation was analyzed at two German cancer centers (LMU Munich and Charité - Universitätsmedizin Berlin) between 2017 and 2021, with focus on colorectal cancer (CRC) patients.

Methods:

In this retrospective analysis, all patients who received a LB between January 2017 and December 2021 as part of routine clinical management were included. To provide adequate context, we collected disease characteristics and technical specifications of the LB methods applied. Additionally, we examined the concordance of RAS status in tumor tissue and LB. Finally, we discuss the potential of LB as a diagnostic tool to drive personalized treatment in CRC patients and how to implement LB in clinical routine.

Results:

In total, our cohort included 86 CRC patients and 161 LB conducted in these patients between 2017 and 2021. In 59 patients, comparison between tissue-based and liquid-based molecular diagnostics, revealed a divergence in 23 (39%) of the evaluable samples.

Conclusion:

Our real-world data analysis indicates that the possibilities of LB are not yet exploited in everyday clinical practice. Currently, the variety of methods and lack of standardization, as well as restricted reimbursement for liquid based CGP hinder the use of LB in clinical routine. To overcome these issues, prospective clinical trials are needed to provide evidence driving the implementation of LB into the management of CRC patients and to support their implementation into clinical guidelines.

• Authors: Laura E Fischer, Sebastian Stintzing, Volker Heinemann, Ulrich Keilholz, Dietmar Keune, Claudia Vollbrecht, Thomas Burmeister, Andreas Kind, Lena Weiss, David Horst, Thomas Kirchner, Frederick Klauschen, Andreas Jung, Christoph Benedikt Westphalen, Ivan Jelas
• Journal: Frontiers in oncology (Front Oncol) Vol. 12 Pg. 870411 ( 2022) ISSN: 2234-943X [Print] Switzerland
• PMID: 35646657 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Fischer, Stintzing, Heinemann, Keilholz, Keune, Vollbrecht, Burmeister, Kind, Weiss, Horst, Kirchner, Klauschen, Jung, Westphalen and Jelas.